These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 324637)

  • 21. [Analysis of antigen-specific proliferation and IL-2/IL-4 production of spleen cells from mice infected with Mycobacterium bovis BCG].
    Teruya K; Kawakami K; Tohyama M; Saito A
    Kekkaku; 1995 Apr; 70(4):293-9. PubMed ID: 7760538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A reduced antigen load in vivo, rather than weak inflammation, causes a substantial delay in CD8+ T cell priming against Mycobacterium bovis (bacillus Calmette-Guérin).
    Russell MS; Iskandar M; Mykytczuk OL; Nash JH; Krishnan L; Sad S
    J Immunol; 2007 Jul; 179(1):211-20. PubMed ID: 17579040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of spleen natural killing activity induced by BCG.
    Ito M; Ralph P; Moore MA
    Clin Immunol Immunopathol; 1980 May; 16(1):30-8. PubMed ID: 6991179
    [No Abstract]   [Full Text] [Related]  

  • 24. Adjuvant activity of mycobacterial fractions. I. Purification and in vivo adjuvant activity of cell wall skeletons of Mycobacterium bovis BCG, Nocardia asteroides 131 and Corynebacterium diphtheriae PW8.
    Azuma I; Kanetsuna F; Taniyama T; Yamamura Y; Hori M
    Biken J; 1975 Mar; 18(1):1-13. PubMed ID: 807194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single strain of Mycobacterium bovis bacillus Calmette-Guérin (BCG) grown in two different media evokes distinct humoral immune responses in mice.
    Petricevich VL; Ueda C; Alves RC; da Silva MA; Moreno C; Melo AR; Dias da Silva W
    Braz J Med Biol Res; 2001 Jan; 34(1):81-92. PubMed ID: 11151032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific and nonspecific antitumor immunity. II. Macrophage-mediated nonspecific effector activity induced by BCG and similar agents.
    Germain RN; Williams RM; Benacerraf B
    J Natl Cancer Inst; 1975 Mar; 54(3):709-20. PubMed ID: 1091741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
    Lu M; Xia ZY; Bao L
    Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of the antibody response in vitro by BCG.
    Brown CA; Brown IN; Sljivíc VS
    Dev Biol Stand; 1977 Apr 13-15; 38():153-8. PubMed ID: 344094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCG immunotherapy of a mucous membrane malignant melanoma. Report of a case.
    Pliskin ME; Mastrangelo MJ; Bellet R; Berkelhammer J
    Oral Surg Oral Med Oral Pathol; 1976 Jul; 42(1):73-9. PubMed ID: 781579
    [No Abstract]   [Full Text] [Related]  

  • 30. Multiple in vitro mechanisms of tumor cytotoxicity demonstrated in the line-1 guinea pig hepatoma model.
    Osteen RT; Piessens WF; David JR; Churchill WH
    J Natl Cancer Inst; 1975 Oct; 55(4):873-8. PubMed ID: 52720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrophage function in tumor-bearing mice: tumoricidal and chemotactic responses of macrophages activated by infection with Mycobacterium bovis, strain BCG.
    Meltzer MS; Stevenson MM
    J Immunol; 1977 Jun; 118(6):2176-81. PubMed ID: 325142
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effect of the immune strategy based on BCG priming and Ag85A/GM-CSF DNA vaccine boosting in mice].
    Tang Q; Dou J; Zhao FS; Chu LL; Pan M; Wang YF
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Jul; 23(7):591-4. PubMed ID: 17618574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis.
    Skinner MA; Ramsay AJ; Buchan GS; Keen DL; Ranasinghe C; Slobbe L; Collins DM; de Lisle GW; Buddle BM
    Immunology; 2003 Apr; 108(4):548-55. PubMed ID: 12667217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new method for quantitation of cell-mediated immunity in the mouse.
    Clark JM; Menduke H; Wheelock EF
    J Reticuloendothel Soc; 1979 Mar; 25(3):255-67. PubMed ID: 374732
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunization of mice after airborne infection with various strains of BCG.
    Lefford MJ
    Am Rev Respir Dis; 1978 Jan; 117(1):103-9. PubMed ID: 339795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macrophage activation for tumor cytotoxicity: induction of tumoricidal macrophages by supernatants of PPD-stimulated Bacillus Calmette-Guérin-immune spleen cell cultures.
    Ruco LP; Meltzer MS
    J Immunol; 1977 Sep; 119(3):889-96. PubMed ID: 330759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shared antigens between Mycobacterium bovis (BCG) and other bacterial species.
    Minden P; McClatchy JK; Cooper R; Bardana EJ; Farr RS
    Science; 1972 Apr; 176(4030):57-8. PubMed ID: 4621967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stimulation of lymphoid cells by components of BCG.
    Mitchell MS; Mokyr MB; Kahane I
    J Natl Cancer Inst; 1975 Dec; 55(6):1337-43. PubMed ID: 1107573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of in vitro cell-mediated reactivity against syngeneic tumor cells by various lymphoid cell populations from Bacillus Calmette-Guérin-tumor-cured, tumor-sensitized, tumor-bearing, and normal inbred guinea pigs.
    Fidler IJ; Kataoka T; Hanna MG
    Cancer Res; 1976 Dec; 36(12):4459-66. PubMed ID: 187324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.